Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Skye Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Skye Bioscience's regulatory disclosures and financial reporting.
Skye Bioscience, Inc. is moving its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market after falling out of compliance with the Global Market’s $10,000,000 minimum stockholders’ equity requirement. The company reported stockholders’ equity of $9,011,804 as of March 31, 2026.
Nasdaq approved the transfer effective with the open of business on June 23, 2026, and the trading symbol “SKYE” will remain unchanged. Separately, Skye previously received notice that its shares traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day compliance period ending September 14, 2026. The company plans to monitor its share price and consider options to regain compliance but notes there is no assurance it will succeed.
Skye Bioscience, Inc. amended its charter to increase the number of authorized common shares from 100,000,000 to 300,000,000. This change does not affect the 35,126,884 common shares that were outstanding and entitled to vote as of April 2, 2026, but expands the shares the company may issue in the future.
The amendment was unanimously approved by the board and then approved by stockholders at the 2026 annual meeting, where a quorum of 23,529,424 shares, or 66.98% of those entitled to vote, was present. Stockholders also elected six directors, ratified CBIZ CPAs P.C. as auditor for 2026, and approved executive compensation on an advisory basis.
Skye Bioscience reported that Nasdaq has notified the company it no longer meets the Nasdaq Global Market stockholders’ equity requirement. Based on its Form 10-Q for the quarter ended March 31, 2026, stockholders’ equity was $9,011,804, below the $10,000,000 minimum under Listing Rule 5450(b)(1)(A).
The notice does not immediately affect trading, and the stock continues on the Nasdaq Global Market under the symbol SKYE. Skye has 45 days, until June 29, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days, to November 9, 2026, if Nasdaq accepts its plan. Failure to regain compliance could ultimately lead to delisting after any appeal process.
Skye Bioscience, Inc. filed an initial Form 3 for Chief Financial Officer John P. Sharp. This filing establishes him as a reporting person for the company’s equity securities. The filing shows no reported transactions or holdings in either common stock or derivative securities at this time.
Skye Bioscience is asking stockholders to vote at a fully virtual 2026 annual meeting while outlining clinical and strategic progress for its obesity program. The company highlights proof-of-concept data for nimacimab, a peripheral CB1 antibody, in combination with semaglutide.
In the CBeyond study, the combination arm reached 22.3% mean weight loss at 52 weeks with additional benefits in waist circumference and lean-to-fat mass ratio, and a safety profile described as placebo-like with no observed nimacimab-associated neuropsychiatric signal. Skye is running a higher-dose expansion, advancing subcutaneous delivery options, and preparing a Phase 2b design incorporating FDA feedback.
On governance, stockholders are asked to elect six directors, ratify CBIZ CPAs P.C. as auditor, approve an amendment to increase authorized common shares from 100,000,000 to 300,000,000, and cast an advisory vote on executive compensation. The board describes its committees, independence, anti-hedging and clawback policies, and a director compensation structure built around cash retainers and stock options.
Skye Bioscience filed its 2026 proxy statement and CEO letter summarizing 2025 progress and items for shareholder vote. The letter highlights CBeyond™ proof-of-concept results for nimacimab combined with semaglutide (26-week additional weight loss; 22.3% mean weight loss at 52 weeks in the combination cohort) and an encouraging safety profile through 52 weeks. The company says the 200 mg weekly monotherapy dose likely underexposed peripheral tissues and has initiated a higher-dose expansion to generate safety and PK data and inform a planned Phase 2b, while advancing a high-concentration formulation and evaluating Halozyme’s ENHANZE® technology for higher-exposure subcutaneous delivery.
The proxy solicits votes to elect six directors, ratify CBIZ CPAs P.C. as auditor, approve an amendment to increase authorized common shares from 100,000,000 to 300,000,000, and to hold an advisory say-on-pay vote. The CEO letter also describes early proof-of-concept for an antibody-peptide conjugate program and ongoing capital discipline and execution priorities for 2026.
Skye Bioscience, Inc. is soliciting proxies for its 2026 virtual annual meeting to elect six directors, ratify CBIZ CPAs P.C. as auditor and seek stockholder approval to amend the Articles of Incorporation to increase authorized common shares from 100,000,000 to 300,000,000. The proxy and CEO letter highlight clinical progress for nimacimab including a 22.3% mean weight loss at 52 weeks in a combination cohort and a move to higher-dose expansion to inform Phase 2b design.
The company emphasizes preparing a Phase 2b plan, advancing higher-concentration subcutaneous formulation work with Halozyme ENHANZE® technology, and developing an antibody-peptide conjugate program. The board recommends voting "For" all proposals; record date and meeting logistics are provided in the proxy materials.
Skye Bioscience, Inc. filed an amended current report to correct a clerical error in an earlier disclosure about stock options. The company now states that the total number of shares of common stock underlying all repriced options is 2,458,158 shares. No other aspects of the prior report were changed.